TPIDB > 臨床試驗主持人
臨床試驗主持人
更新時間：2023-09-19
姚明YAO, MING
- 計畫主持人
- 執行臨床試驗年資 23 年 9 個月
發表文獻
13筆
1
Ma WL, Yeh KH, Yao M, Tang JL, Lin CW, Wang YT, Yeh YC, Wang HP, Cheng AL, Kuo SH. Comparison of clinicopathological features and treatment outcomes in aggressive primary intestinal B- and T/NK-cell lymphomas. J Formos Med Assoc. 2021 Jan;120(1 Pt 2):293-302. doi: 10.1016/j.jfma.2020.10.001. Epub 2020 Oct 21. PMID: 33289640.
2
Tsai CH, Tang JL, Tien FM, Kuo YY, Wu DC, Lin CC, Tseng MH, Peng YL, Hou MF, Chuang YK, Liu MC, Liu CW, Yao M, Lin LI, Chou WC, Chen CY, Hou HA, Tien HF. Clinical implications of sequential MRD monitoring by NGS at 2 time points after chemotherapy in patients with AML. Blood Adv. 2021 May 25;5(10):2456-2466. doi: 10.1182/bloodadvances.2020003738. PMID: 33999144; PMCID: PMC8152512.
3
Wang YW, Tsai CH, Lin CC, Tien FM, Chen YW, Lin HY, Yao M, Lin YC, Lin CT, Cheng CL, Tang JL, Chou WC, Hou HA, Tien HF. Cytogenetics and mutations could predict outcome in relapsed and refractory acute myeloid leukemia patients receiving BCL-2 inhibitor venetoclax. Ann Hematol. 2020 Mar;99(3):501-511. doi: 10.1007/s00277-020-03911-z. Epub 2020 Jan 21. PMID: 31965269.
4
Hsu CR, Chen YY, Yao M, Wei YH, Hsieh YT, Liao SL. Orbital and ocular adnexal lymphoma: a review of epidemiology and prognostic factors in Taiwan. Eye (Lond). 2021 Jul;35(7):1946-1953. doi: 10.1038/s41433-020-01198-y. Epub 2020 Sep 29. PMID: 32994547; PMCID: PMC8225637.
5
Wang YH, Lin CC, Lee SH, Tsai CH, Wu SJ, Hou HA, Huang TC, Kuo YY, Yao M, Chang K, Lin CW, Lin YC, Tien FM, Chou WC, Tang JL, Tien HF. ASXL1 mutation confers poor prognosis in primary myelofibrosis patients with low JAK2V617F allele burden but not in those with high allele burden. Blood Cancer J. 2020 Oct 12;10(10):99. doi: 10.1038/s41408-020-00364-5. PMID: 33046688; PMCID: PMC7550588.
6
Wang YH, Yu SC, Ko BS, Yang YT, Yao M, Tang JL, Huang TC. Correlative analysis of overall survival with clinical characteristics in 127 patients with mantle cell lymphoma: a multi-institutional cohort in Taiwan. Int J Hematol. 2020 Sep;112(3):385-394. doi: 10.1007/s12185-020-02903-z. Epub 2020 Jun 9. PMID: 32519171.
7
Wu SH, Hsieh CC, Hsu SC, Yao M, Hsiao JK, Wang SW, Lin CP, Huang DM. RBC-derived vesicles as a systemic delivery system of doxorubicin for lysosomal-mitochondrial axis-improved cancer therapy. J Adv Res. 2020 Nov 24;30:185-196. doi: 10.1016/j.jare.2020.11.009. PMID: 34026295; PMCID: PMC8132207.
8
Huang HH, Chen FY, Chou WC, Hou HA, Ko BS, Lin CT, Tang JL, Li CC, Yao M, Tsay W, Hsu SC, Wu SJ, Chen CY, Huang SY, Tseng MH, Tien HF, Chen RH. Long non-coding RNA HOXB-AS3 promotes myeloid cell proliferation and its higher expression is an adverse prognostic marker in patients with acute myeloid leukemia and myelodysplastic syndrome. BMC Cancer. 2019 Jun 24;19(1):617. doi: 10.1186/s12885-019-5822-y. PMID: 31234830; PMCID: PMC6591843.
9
Tsai CH, Yao CY, Tien FM, Tang JL, Kuo YY, Chiu YC, Lin CC, Tseng MH, Peng YL, Liu MC, Liu CW, Yao M, Lin LI, Chou WC, Chen CY, Hou HA, Tien HF. Incorporation of long non-coding RNA expression profile in the 2017 ELN risk classification can improve prognostic prediction of acute myeloid leukemia patients. EBioMedicine. 2019 Feb;40:240-250. doi: 10.1016/j.ebiom.2019.01.022. Epub 2019 Jan 17. PMID: 30662003; PMCID: PMC6413345.
10
Liu JH, Liao XW, Chen CH, Yao M, Li CC, Lin CT, Tsai CH, Chou WC, Hou HA, Huang SY, Wu SJ, Chen YC, Tien HF, Tang JL, Ko BS. Adoptive donor immunity protects against resolved hepatitis B virus reactivation after allogeneic haematopoietic stem cell transplantation in the world's largest retrospective cohort study. Br J Haematol. 2019 Jul;186(1):72-85. doi: 10.1111/bjh.15884. Epub 2019 Mar 28. PMID: 30919947.
1
2
